• About
    ▼
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    ▼
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Publications
  • Pipeline
    ▼
    • Overview
    • ABC008
    • IBM
    • T-LGLL
    • Additional Indications
    • ABC015
  • News
  • Careers
  • Contact
About

About

Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

  • About
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Publications
  • Pipeline
    • Overview
    • ABC008
    • IBM
    • T-LGLL
    • Additional Indications
    • ABC015
  • News
  • Careers
  • Contact

Hafler, Jason P. , PhD

March 7, 2022

Jason P. Hafler is the Managing Director of Sanofi Ventures. Prior to joining Sanofi in 2014, Jason was the Director of Corporate Development at RaNA Therapeutics, a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm.  Jason’s active investments include Abcuro, Amathus Therapeutics, Escient Pharmaceuticals, Expansion Therapeutics, Glycomine, Q32 Bio, ReCode Therapeutics, Rome Therapeutics and Navitor Pharmaceuticals. Jason graduated with honors from Bowdoin College and holds a Ph.D. from the University of Cambridge.

Jason P. Hafler, PhD

Managing Director, Sanofi Ventures

x

Jason P. Hafler, PhD

Managing Director, Sanofi Ventures

Jason P. Hafler is the Managing Director of Sanofi Ventures. Prior to joining Sanofi in 2014, Jason was the Director of Corporate Development at RaNA Therapeutics, a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm.  Jason’s active investments include Abcuro, Amathus Therapeutics, Escient Pharmaceuticals, Expansion Therapeutics, Glycomine, Q32 Bio, ReCode Therapeutics, Rome Therapeutics and Navitor Pharmaceuticals. Jason graduated with honors from Bowdoin College and holds a Ph.D. from the University of Cambridge.

Privacy Site Credits Terms of Use

© 2023 Abcuro